Clinical trialPhase 2Enrolling by invitation
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
A Prospective, Single-Arm Study of Nimotuzumab Combined With NALIRIFOX Regimen as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Enrolling by invitation
- Study type
- Interventional
- Start
- 6 June 2026
- Expected end
- 10 August 2028
- Enrollment
- 45 participants
- Sites
- 1
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients. All patients will receive nimotuzumab combined with the NALIRIFOX chemotherapy regimen as first-line treatment. Nimotuzumab is a targeted antibody against EGFR. NALIRIFOX is a standard first-line chemotherapy regimen for advanced pancreatic cancer and includes liposomal irinotecan, oxaliplatin, leucovorin, and 5-FU. Nimotuzumab 400 mg will be given intravenously on Day 1 every 2 weeks. The NALIRIFOX regimen will also be given every 2 weeks. Treatment will continue until the cancer grows or the side effects become unacceptable. The main purpose of this study is to find out how long patients live without their cancer getting worse (progression-free survival, PFS). The study will also look at overall survival, tumor response rate, disease control rate, time to progression, and safety, especially serious side effects. Patients will be followed closely during treatment. Imaging tests will be done every 8 weeks to check the cancer. After treatment ends, patients will be followed for survival for up to 24 months after the last patient is enrolled.